DexCom (NASDAQ:DXCM - Get Free Report) is scheduled to issue its quarterly earnings data after the market closes on Thursday, April 25th. Analysts expect the company to announce earnings of $0.27 per share for the quarter. Parties that wish to register for the company's conference call can do so using this link.
DexCom (NASDAQ:DXCM - Get Free Report) last announced its earnings results on Thursday, February 8th. The medical device company reported $0.50 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.43 by $0.07. DexCom had a net margin of 14.95% and a return on equity of 28.31%. The business had revenue of $1.03 billion during the quarter, compared to analysts' expectations of $1.02 billion. During the same quarter last year, the company posted $0.34 EPS. The firm's revenue for the quarter was up 26.9% on a year-over-year basis. On average, analysts expect DexCom to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.
DexCom Price Performance
NASDAQ:DXCM traded up $0.44 during mid-day trading on Thursday, reaching $134.30. 2,116,042 shares of the company were exchanged, compared to its average volume of 2,984,076. DexCom has a 12 month low of $74.75 and a 12 month high of $142.00. The company has a fifty day moving average of $129.20 and a 200 day moving average of $116.28. The company has a quick ratio of 2.48, a current ratio of 2.84 and a debt-to-equity ratio of 1.18. The stock has a market cap of $51.78 billion, a PE ratio of 102.18, a PEG ratio of 2.35 and a beta of 1.20.
Insiders Place Their Bets
In other DexCom news, CFO Jereme M. Sylvain sold 3,363 shares of the firm's stock in a transaction that occurred on Tuesday, February 20th. The shares were sold at an average price of $116.73, for a total transaction of $392,562.99. Following the sale, the chief financial officer now directly owns 71,142 shares in the company, valued at approximately $8,304,405.66. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other news, CFO Jereme M. Sylvain sold 3,363 shares of DexCom stock in a transaction that occurred on Tuesday, February 20th. The shares were sold at an average price of $116.73, for a total value of $392,562.99. Following the sale, the chief financial officer now directly owns 71,142 shares in the company, valued at $8,304,405.66. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Kevin R. Sayer sold 81,007 shares of DexCom stock in a transaction that occurred on Tuesday, March 12th. The shares were sold at an average price of $133.36, for a total transaction of $10,803,093.52. Following the completion of the sale, the chief executive officer now owns 333,526 shares in the company, valued at $44,479,027.36. The disclosure for this sale can be found here. In the last three months, insiders have sold 189,375 shares of company stock worth $25,530,859. Company insiders own 0.41% of the company's stock.
Institutional Trading of DexCom
Hedge funds and other institutional investors have recently made changes to their positions in the business. Norges Bank bought a new position in shares of DexCom in the fourth quarter valued at $421,378,000. Price T Rowe Associates Inc. MD grew its stake in shares of DexCom by 64.6% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 5,499,896 shares of the medical device company's stock valued at $682,483,000 after buying an additional 2,157,933 shares in the last quarter. 1832 Asset Management L.P. bought a new position in shares of DexCom in the fourth quarter valued at $151,538,000. Clearbridge Investments LLC grew its stake in shares of DexCom by 304.3% in the first quarter. Clearbridge Investments LLC now owns 1,318,079 shares of the medical device company's stock valued at $674,329,000 after buying an additional 992,049 shares in the last quarter. Finally, Voya Investment Management LLC grew its stake in shares of DexCom by 25.9% in the fourth quarter. Voya Investment Management LLC now owns 3,308,700 shares of the medical device company's stock valued at $410,577,000 after buying an additional 680,928 shares in the last quarter. 97.75% of the stock is currently owned by institutional investors and hedge funds.
Analyst Ratings Changes
A number of brokerages have commented on DXCM. Citigroup increased their price objective on shares of DexCom from $148.00 to $161.00 and gave the stock a "buy" rating in a report on Wednesday, April 3rd. Royal Bank of Canada began coverage on shares of DexCom in a research note on Tuesday, March 12th. They issued an "outperform" rating and a $165.00 target price on the stock. UBS Group raised their target price on shares of DexCom from $153.00 to $163.00 and gave the company a "buy" rating in a research note on Wednesday, April 10th. Raymond James raised their target price on shares of DexCom from $147.00 to $151.00 and gave the company a "strong-buy" rating in a research note on Tuesday, January 23rd. Finally, StockNews.com raised shares of DexCom from a "hold" rating to a "buy" rating in a research note on Wednesday, April 3rd. Two analysts have rated the stock with a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $141.40.
Read Our Latest Stock Analysis on DexCom
About DexCom
(
Get Free Report)
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.
Featured Stories
Before you consider DexCom, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DexCom wasn't on the list.
While DexCom currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
